Myriad Genetics (NASDAQ: MYGN) COO receives 32,810 performance-based stock units

Rhea-AI Filing Summary

Myriad Genetics Chief Operating Officer Mark Verratti reported an award of common stock tied to earlier performance-based restricted stock units. On February 2, 2026, he acquired 32,810 shares of common stock at $0 per share, following certification of performance goals. After this award, he beneficially owned 414,636 shares directly. The underlying performance-based units were originally granted on March 15, 2023 and are scheduled to vest on March 15, 2026, with each unit representing one share of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Verratti Mark

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	32,810	$0.00	--

Holdings After Transaction: Common Stock — 414,636 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verratti Mark

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A		32,810(1)	A	$0	414,636	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of performance-based restricted stock units (PSUs) initially granted on March 15, 2023, subject to accomplishment of pre-determined performance metrics. On February 2, 2026, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 15, 2026.

Remarks:

	By: Justin Hunter For: Mark Verratti	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MYGN Chief Operating Officer Mark Verratti report?

Mark Verratti reported acquiring 32,810 shares of Myriad Genetics common stock for $0 per share. The shares relate to performance-based restricted stock units granted in March 2023 after performance metrics were certified, increasing his direct beneficial ownership to 414,636 shares.

What is the origin of the 32,810 MYGN shares reported in this Form 4?

The 32,810 Myriad Genetics shares stem from performance-based restricted stock units initially granted on March 15, 2023. The Compensation and Human Capital Committee determined the final award on February 2, 2026, based on predefined performance metrics linked to that original grant.

When do the performance-based restricted stock units for MYGN vest?

The performance-based restricted stock units linked to this Form 4 are scheduled to vest on March 15, 2026. Each unit represents a contingent right to receive one share of Myriad Genetics common stock once the vesting date and applicable conditions are satisfied.

How many MYGN shares does Mark Verratti own after this reported transaction?

After this transaction, Mark Verratti beneficially owns 414,636 shares of Myriad Genetics common stock directly. This total includes the 32,810 shares issued for achieving performance conditions set under the March 15, 2023 performance-based restricted stock unit award.

What role did the Compensation and Human Capital Committee play in this MYGN award?

The Compensation and Human Capital Committee determined the final award amount for the performance-based restricted stock units on February 2, 2026. Their decision was based on the accomplishment of the applicable pre-determined performance metrics defined when the units were initially granted in March 2023.

What does the transaction price of $0 mean in this MYGN Form 4 filing?

The $0 transaction price indicates the shares were granted without a cash purchase price to Mark Verratti. They were issued upon achievement of performance goals tied to previously granted performance-based restricted stock units, rather than acquired through an open-market or option exercise purchase.